Determining the price for pharmaceuticals in Germany: Comparing a shortcut for IQWiG's efficiency frontier method with the price set by the manufacturer for ticagrelor

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 14, Issue 1, 2014, Pages 123-129

  Gandjour, Afschin ^a   Gafni, Amiram ^b   Schlander, Michael ^c  

^a FRANKFURT SCHOOL OF FINANCE AND MANAGEMENT   (Germany)

^b MCMASTER UNIVERSITY   (Canada)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Drug pricing; Germany; IQWiG; Ticagrelor

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; PLACEBO; TICAGRELOR;

ADULT; ARTICLE; BLEEDING; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; COST CONTROL; DRUG COST; DRUG FATALITY; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG SAFETY; FEMALE; GERMANY; HEALTH CARE ORGANIZATION; HEALTH CARE QUALITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; REIMBURSEMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION;

ADENOSINE; COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; DELIVERY OF HEALTH CARE; DRUG INDUSTRY; GERMANY; HEALTH CARE COSTS; HUMANS; PLATELET AGGREGATION INHIBITORS; REIMBURSEMENT MECHANISMS;

EID: 84893028651     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/14737167.2014.868313     Document Type: Article

References (18)

1. Institute for Quality and Efficiency in Health Care. Ticagrelor - Benefit Assessment According to § 35a Social Code Book V (in German). Institute for Quality and Efficiency in Health Care, Cologne, Germany (2011
2. Wallentin L, Becker RC, Budaj A et al.; PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 361(11), 1045-1057 (2009
3. Institute for Quality and Efficiency in Health Care. General Methods for the Assessment of the Relation of Benefits to Costs - Version 1.0 (in German). Institute for Quality and Efficiency in Health Care, Cologne, Germany (2009
4. Gandjour A. Germany's decision rule for cost-effectiveness analysis on drugs: A comparative analysis with other decision rules. Appl. Health Econ. Health Policy 9(2), 65-71 (2011
5. Gandjour A. Presenting Germany's drug pricing rule as a cost-per-QALY rule. Health Care Manag. Sci. 15(2), 103-107 (2012
6. Gandjour A, Gafni A. The German method for setting ceiling prices for drugs: In some cases less data are required. Expert Rev. Pharmacoecon. Outcomes Res. 11(4), 403-409 (2011
7. Gandjour A Reference pricing and price negotiations for innovative new drugs: Viable policies in the long term? Pharmacoeconomics 31(1), 11-14 (2013
8. Institute for Quality and Efficiency in Health Care. Clopidogrel Plus Acetylsalicylic Acid in Acute Coronary Syndrome (in German). Institute for Quality and Efficiency in Health Care, Cologne, Germany (2009
9. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK; Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med. 345(7), 494-502 (2001
10. Serebruany VL. Viewpoint: Paradoxical excess mortality in the PLATO trial should be independently verified. Thromb. Haemost. 105(5), 752-759 (2011
11. Tsevat J, Goldman L, Soukup JR et al. Stability of time-tradeoff utilities in survivors of myocardial infarction. Med. Decis. Making 13(2), 161-165 (1993
12. Günther K. Identifikation von Risikogruppen für myokardinfarktbedingte Letalität und nicht-Leitliniengerechte Versorgung unter Patienten mit Nicht-ST-Streckenhebungs- Myokardinfarkt (NSTEMI) oder STStreckenhebungs- Myokardinfarkt (STEMI) in Bremen. University of Bremen, Bremen, Germany (2010
13. Birch S, Gafni A. Cost effectiveness/utility analyses. Do current decision rules lead us to where we want to bëJ. Health Econ. 11(3), 279-296 (1992
14. Birch S, Gafni A. Changing the problem to fit the solution: Johannesson and Weinstein's (mis) application of economics to real world problems. J. Health Econ. 12(4), 469-476 (1993
15. Weinstein MC, Zeckhauser R. Critical ratios and efficient allocation. J. Public Econ. 2, 147-157 (1973
16. Schlander M, Jaecker A, Voelkl M. Arzneimittelpreise: Preisbildung in einem besonderen Markt. Dtsch Ärztebl. 109(11), A524-A528 (2012
17. Schlander M, Jaecker A, Voelkl M. Arzneimittelpreisregulierung nach den Prinzipien der Sozialen Marktwirtschaft. PharmInd. 75(3), 384-389 (2013
18. Cost-Effectiveness in Health and Medicine. Gold MR, Siegel JE, Russell LB, Weinstein MC (Eds). Oxford University Press, NY, USA (1996